Study explores parents’ struggle with children’s avid eating behaviors

Re­searchers should re­think how they fi­nance clin­i­cal tri­als for chil­dren’s can­cers in or­der to boost in­vest­ment in pe­di­atric on­col­o­gy R&D, ac­cord­ing to a new pa­per

The deal is centred around G1’s lead cyclin-dependent kinase 4/6 (CDK4/6) inhibitor Cosela (trilaciclib), which generated $46.3m in sales last year. Image Credit: Golden Sikorka

A BIOVECTRA manufacturing facility. Credit: Agilent Technologies, Inc. / Business Wire. Agilent Technologies has announced a definitive agreement for the acquisition of Canadian contract development